Dyrenium
(Triamterene)ApprovedSmall molecule
Dyrenium is one of 11 small molecule programs targeting Proteinuria. It is currently in Approved.
1
Indications
3
Total Trials
0
Active Trials
10
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Proteinuria
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Zemplar
AbbVieApproved
Trental
VValidus Pharmaceuticals
Approved
Midamor
PPadagis LLC
Approved
Filspari
TTravere Therapeutics, Inc.
Approved
Dyrenium
AAdvanz Pharma
Approved
Cysteine Hydrochloride
NovartisPreclinical
Tyzeka
NovartisPreclinical
AP1189
SSynAct Pharma Aps
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Drug Repurposing1 trial
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
Completed·—··NCT05125237·155,963 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DYRENIUM
NDA NDA013174
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triamterene. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAdvanz Pharma